GTHX · G1 Therapeutics
Acquired Company
Pharmacosmos Group completed the acquisition of G1 Therapeutics on 9/18/2024 for US $7.15 per share in cash, representing a total equity value of approximately $405 million.
G1 Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the discovery, development and delivery of next generation therapies that improve the lives of those affected by cancer, including the Company's first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline evaluating targeted cancer therapies in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C.
Market Cap
N/A
52 Wk Range
N/A - N/A
Previous Close
$7.15
Open
$7.15
Volume
N/A
Day Range
$7.15 - $7.15
Enterprise Value
N/A
Cash
N/A
Avg Qtr Burn
N/A
Insider Ownership
10.92%
Institutional Own.
54.62%
Qtr Updated
Jun 30th 2024